It is imaginable that cognate interaction between DC presenting tumor antigen and specific T cells within TDLN, further enhanced by PD-1/PD-L1 blocking antibodies, contributes to anti-tumor immunity, leading to a greater pool of tumor-specific T cells available for tumor eradication (Figure 1). This evidence concerns the gene CD274 and neoplasm.